Combination of PARP inhibitors and c-MET may benefit breast cancer patientshealthmedicinetJanuary 19, 2016news / no comments University of Texas M. D. Anderson Cancer Center Related posts: HMN 2025: How Omomyc enhances PARP inhibitor effects and overcomes resistance in breast cancer models HMN 2025: How Stopping DNA damage in T cells during PARP inhibitor cancer treatment enhances antitumor effectiveness Previous Post Immunity genes could protect some from E. coli while others fall ill Next Post New tool puts accurate DNA analysis in fast lane
